AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
Go back to AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin| AbbVie (NYSE: ABBV) | Delayed: 258.32 -4.58 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.90 | 52 Week High | $68.12 | |||
| Open | $260.81 | 52 Week Low | $50.71 | |||
| Day High | $262.50 | P/E | 56.03 | |||
| Day Low | $257.25 | EPS | $4.61 | |||
| Volume | 2,016,132 | |||||
